Amarin (AMRN) pre-announced record quarterly sales of its heart drug Vascepa on Tuesday and raised its financial guidance for the remainder of the year, citing strong patient demand for the drug, derived from fish oil, now that it has been shown to significantly lower the risk of death and other adverse cardiovascular events.

The Bedminster, New Jersey-based drug maker is also doubling the size of its commercial salesforce to prepare for the highly expected expansion of Vascepa’s label by the Food and Drug Administration in late September, the company said. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I take Vascepa twice daily. My medical professional prescribed this for me several years ago. Of course my insurance will not pay for me to take it. I Have been able to get samples from my Doctor thank him. I can’t believe how much this medication has helped me with no side effects. Just great.

  • Vascepa is really a life saver for many. A BP acquisition will make the marketing more efficient with their established sales force, a win-win.

  • Excellent article Mr. Feuerstein. My belief is that you were right when
    you indicated that AMRN should be acquired by a BP with a strong
    Cardiovascular sales arm. I would expect Pfizer, Novartis, Amgen,
    and Johnson & Johnson to be the best candidates to acquire Amarin.
    However, would not count out GILD, LLY, or NVO. Just a matter of time.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy